Molecular pathways: Anticancer activity by inhibition of nucleocytoplasmic shuttling

Fabio Conforti, Yisong Wang, Jose A. Rodriguez, Anna Teresa Alberobello, Yu Wen Zhang, Giuseppe Giaccone

Research output: Contribution to journalArticlepeer-review


A dynamic distribution between nucleus and cytoplasm (nucleocytoplasmic shuttling) is one of the control mechanisms adapted by normal cells to regulate the activity of a variety of molecules. Growing evidence suggests that dysregulation of the nucleocytoplasmic shuttling is involved in promoting abnormal cell survival, tumor progression, and drug resistance, and is associated with poor cancer prognosis. Aberrant nucleocytoplasmic shuttling in cancer cells mayresult from a hyperactive status of diverse signal-transduction pathways, such as the PI3K-AKT and MAPK pathways, or from alterations in the general nuclear import/export machinery. Among the large number of molecules involved in the shuttling process, exportin XPO1, also known as chromosome region maintenance 1, appears to play a particularly prominent role in pathogenesis of both hematological malignancies and solid tumors. Given the importance of nucleocytoplasmic shuttling in cancer pathogenesis and the rapidly expanding knowledge in this field, attempts have been made to develop compounds able to revert the aberrant nucleocytoplasmic shuttling. A promising new drug, KPT-330 (Selinexor), which belongs to the class of XPO1 inhibitors called selective inhibitors of nuclear export, is now being tested in phase I/II clinical trials.

Original languageEnglish
Pages (from-to)4508-4513
Number of pages6
JournalClinical Cancer Research
Issue number20
Publication statusPublished - Oct 15 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Molecular pathways: Anticancer activity by inhibition of nucleocytoplasmic shuttling'. Together they form a unique fingerprint.

Cite this